
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections
Iris Medits, David Niklas Springer, Marianne Graninger, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 40
Iris Medits, David Niklas Springer, Marianne Graninger, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 40
Showing 1-25 of 40 citing articles:
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Young‐Jun Park, Dora Pinto, Alexandra C. Walls, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 37
Young‐Jun Park, Dora Pinto, Alexandra C. Walls, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 37
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
H. J. Yang, Weiqi Hong, Lei Hong, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 36
H. J. Yang, Weiqi Hong, Lei Hong, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 36
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Dennis Lapuente, Thomas Winkler, Matthias Tenbusch
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 144-158
Open Access | Times Cited: 29
Dennis Lapuente, Thomas Winkler, Matthias Tenbusch
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 144-158
Open Access | Times Cited: 29
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
David Niklas Springer, Michael Bauer, Iris Medits, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 26
David Niklas Springer, Michael Bauer, Iris Medits, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 26
Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant
David Niklas Springer, Thomas Perkmann, Claudia Jani, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 30
David Niklas Springer, Thomas Perkmann, Claudia Jani, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 30
Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies
Pia Gattinger, Anna Ohradanova‐Repic, Rudolf Valenta
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5352-5352
Open Access | Times Cited: 19
Pia Gattinger, Anna Ohradanova‐Repic, Rudolf Valenta
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5352-5352
Open Access | Times Cited: 19
HLA Variation and SARS-CoV-2 Specific Antibody Response
Dawit Wolday, Chun Yiu Jordan Fung, Gregory Morgan, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 906-906
Open Access | Times Cited: 16
Dawit Wolday, Chun Yiu Jordan Fung, Gregory Morgan, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 906-906
Open Access | Times Cited: 16
Immunological imprinting of humoral immunity to SARS-CoV-2 in children
Alexander C. Dowell, Tara Lancaster, Rachel Bruton, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Alexander C. Dowell, Tara Lancaster, Rachel Bruton, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Immune interference in effectiveness of influenza and COVID-19 vaccination
Yiwen Xie, Xuebin Tian, Xiaodi Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Yiwen Xie, Xuebin Tian, Xiaodi Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Neutralization of SARS‐CoV‐2 Omicron XBB.1.5 and JN.1 variants after COVID‐19 booster‐vaccination and infection
David Niklas Springer, Jeremy V. Camp, Stephan W. Aberle, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 7
Open Access | Times Cited: 6
David Niklas Springer, Jeremy V. Camp, Stephan W. Aberle, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 7
Open Access | Times Cited: 6
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
Felix Kartnig, Daniel Mrak, Elisabeth Simader, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 292-300
Open Access | Times Cited: 22
Felix Kartnig, Daniel Mrak, Elisabeth Simader, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 292-300
Open Access | Times Cited: 22
Immune Response to COVID-19 mRNA Vaccination in Previous Nonresponder Kidney Transplant Recipients After Short-term Withdrawal of Mycophenolic Acid 1 and 3 Months After an Additional Vaccine Dose
Tessa Kühn, Claudius Speer, Christian Morath, et al.
Transplantation (2023) Vol. 107, Iss. 5, pp. 1139-1150
Open Access | Times Cited: 14
Tessa Kühn, Claudius Speer, Christian Morath, et al.
Transplantation (2023) Vol. 107, Iss. 5, pp. 1139-1150
Open Access | Times Cited: 14
Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations Using a Multivariant Surrogate Virus Neutralization Microarray
David Niklas Springer, Eva Höltl, Katja Prüger, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 94-94
Open Access | Times Cited: 3
David Niklas Springer, Eva Höltl, Katja Prüger, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 94-94
Open Access | Times Cited: 3
Three rounds of a national external quality assessment reveal a link between disharmonic anti-SARS-CoV-2 antibody quantifications and the infection stage
Christoph Buchta, David Niklas Springer, Jovana Jovanović, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2023) Vol. 61, Iss. 7, pp. 1349-1358
Open Access | Times Cited: 9
Christoph Buchta, David Niklas Springer, Jovana Jovanović, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2023) Vol. 61, Iss. 7, pp. 1349-1358
Open Access | Times Cited: 9
An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants
Muhammad Zafar Irshad Khan, Adila Nazli, Hawaa Al-furas, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
Muhammad Zafar Irshad Khan, Adila Nazli, Hawaa Al-furas, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
A Multivariant Surrogate Neutralization Assay Identifies Variant-Specific Neutralizing Antibody Profiles in Primary SARS-CoV-2 Omicron Infection
David Niklas Springer, Marianna Traugott, Elisabeth Reuberger, et al.
Diagnostics (2023) Vol. 13, Iss. 13, pp. 2278-2278
Open Access | Times Cited: 8
David Niklas Springer, Marianna Traugott, Elisabeth Reuberger, et al.
Diagnostics (2023) Vol. 13, Iss. 13, pp. 2278-2278
Open Access | Times Cited: 8
SARS-CoV-2 Neutralizing Antibodies in Three African Countries Following Multiple Distinct Immune Challenges
Diary Juliannie Ny Mioramalala, Rila Ratovoson, Paul Alain Tagnouokam‐Ngoupo, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 363-363
Open Access | Times Cited: 2
Diary Juliannie Ny Mioramalala, Rila Ratovoson, Paul Alain Tagnouokam‐Ngoupo, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 363-363
Open Access | Times Cited: 2
Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection
Jinsoo Kim, Hyeonji Seo, Han-Wool Kim, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2458-2458
Open Access | Times Cited: 13
Jinsoo Kim, Hyeonji Seo, Han-Wool Kim, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2458-2458
Open Access | Times Cited: 13
SARS-CoV-2 Neutralizing Antibodies in Three African Countries Following Multiple Distinct Immune Challenges
Diary Juliannie Ny Mioramalala, Rila Ratovoson, Paul Alain Tagnouokam‐Ngoupo, et al.
(2024)
Open Access | Times Cited: 1
Diary Juliannie Ny Mioramalala, Rila Ratovoson, Paul Alain Tagnouokam‐Ngoupo, et al.
(2024)
Open Access | Times Cited: 1
Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patients
Louise Platen, Bo‐Hung Liao, Myriam Tellenbach, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. 12, pp. 2447-2460
Open Access | Times Cited: 3
Louise Platen, Bo‐Hung Liao, Myriam Tellenbach, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. 12, pp. 2447-2460
Open Access | Times Cited: 3
Immunological imprinting of humoral immunity to SARS-CoV-2 in children
Alexander C. Dowell, Tara Lancaster, Rachel Bruton, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Alexander C. Dowell, Tara Lancaster, Rachel Bruton, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination schedule.
Angelika Wagner, Anna Ohradanova‐Repic, Laura Gebetsberger, et al.
Immunology Letters (2022) Vol. 250, pp. 1-6
Open Access | Times Cited: 4
Angelika Wagner, Anna Ohradanova‐Repic, Laura Gebetsberger, et al.
Immunology Letters (2022) Vol. 250, pp. 1-6
Open Access | Times Cited: 4
A rational strategy for the maintenance of antiviral immunity to new SARS-CoV-2 strains
Владимир П. Баклаушев, Gaukhar M. Yusubalieva, Mikhail V. Bychinin, et al.
Journal of clinical practice (2022) Vol. 13, Iss. 3, pp. 43-55
Open Access | Times Cited: 4
Владимир П. Баклаушев, Gaukhar M. Yusubalieva, Mikhail V. Bychinin, et al.
Journal of clinical practice (2022) Vol. 13, Iss. 3, pp. 43-55
Open Access | Times Cited: 4
A Multivariant Surrogate Virus Neutralization Test Demonstrates Distinct SARS-CoV-2-Specific Antibody Responses in People Living with HIV after a Fourth Monovalent mRNA Vaccination or an Omicron Breakthrough Infection
David Niklas Springer, Simon Daller, Michael Knappik, et al.
Diagnostics (2024) Vol. 14, Iss. 8, pp. 822-822
Open Access
David Niklas Springer, Simon Daller, Michael Knappik, et al.
Diagnostics (2024) Vol. 14, Iss. 8, pp. 822-822
Open Access
Cilgavimab and tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA.2 and BA.4/5 variants—a prospective cohort study (RESCUE-TX)
Roman Reindl‐Schwaighofer, Andreas Heinzel, Lukas Raab, et al.
EBioMedicine (2024) Vol. 109, pp. 105417-105417
Open Access
Roman Reindl‐Schwaighofer, Andreas Heinzel, Lukas Raab, et al.
EBioMedicine (2024) Vol. 109, pp. 105417-105417
Open Access